AR034139A1 - Uso de complejos metalicos que contienen perfluoralquilo como medios de contraste para representar placas, tumores y necrosis en imagenes por resonancia magnetica - Google Patents

Uso de complejos metalicos que contienen perfluoralquilo como medios de contraste para representar placas, tumores y necrosis en imagenes por resonancia magnetica

Info

Publication number
AR034139A1
AR034139A1 ARP010103833A ARP010103833A AR034139A1 AR 034139 A1 AR034139 A1 AR 034139A1 AR P010103833 A ARP010103833 A AR P010103833A AR P010103833 A ARP010103833 A AR P010103833A AR 034139 A1 AR034139 A1 AR 034139A1
Authority
AR
Argentina
Prior art keywords
magnetic resonance
metal complexes
perfluoralquilo
necrosis
tumors
Prior art date
Application number
ARP010103833A
Other languages
English (en)
Spanish (es)
Inventor
Platzek Johannes Dr
Mareski Peter Dr
Niedballa Ulrich Dr
Raduchel Bernd Dr
Weinmann Hanns-Joachim Dr
Misselwitz Bernd Dr
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10040380A external-priority patent/DE10040380B4/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR034139A1 publication Critical patent/AR034139A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP010103833A 2000-08-11 2001-08-10 Uso de complejos metalicos que contienen perfluoralquilo como medios de contraste para representar placas, tumores y necrosis en imagenes por resonancia magnetica AR034139A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10040380A DE10040380B4 (de) 2000-08-11 2000-08-11 Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques

Publications (1)

Publication Number Publication Date
AR034139A1 true AR034139A1 (es) 2004-02-04

Family

ID=7652860

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103833A AR034139A1 (es) 2000-08-11 2001-08-10 Uso de complejos metalicos que contienen perfluoralquilo como medios de contraste para representar placas, tumores y necrosis en imagenes por resonancia magnetica

Country Status (26)

Country Link
EP (1) EP1307236A2 (sh)
JP (1) JP2004506025A (sh)
KR (1) KR20030022387A (sh)
CN (1) CN1469757A (sh)
AR (1) AR034139A1 (sh)
AU (2) AU2001277549B2 (sh)
BG (1) BG107542A (sh)
BR (1) BR0113188A (sh)
CA (1) CA2419223A1 (sh)
CZ (1) CZ2003392A3 (sh)
DE (1) DE10066210B4 (sh)
EE (1) EE200300061A (sh)
HR (1) HRP20030173A2 (sh)
HU (1) HUP0300736A3 (sh)
IL (1) IL154385A0 (sh)
MX (1) MXPA03001287A (sh)
NO (1) NO20030604L (sh)
NZ (1) NZ523932A (sh)
PL (1) PL365596A1 (sh)
RU (1) RU2290206C2 (sh)
SK (1) SK1572003A3 (sh)
TW (1) TWI296931B (sh)
UA (1) UA82642C2 (sh)
WO (1) WO2002013874A2 (sh)
YU (1) YU10603A (sh)
ZA (1) ZA200301949B (sh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
DE102006021495A1 (de) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
US7887835B2 (en) * 2006-09-19 2011-02-15 Fujifilm Corporation Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound
DE102006049821A1 (de) * 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
JP2011190183A (ja) * 2010-03-11 2011-09-29 Noguchi Institute フルオラス化糖結合型クラウンエーテル誘導体
US9976072B2 (en) 2014-03-26 2018-05-22 Chevron U.S.A. Inc. Multicarboxylate compositions and method of making the same
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
JP7037069B2 (ja) * 2016-09-14 2022-03-16 ダイキン工業株式会社 分枝含フッ素化合物
RU2755181C2 (ru) 2016-11-28 2021-09-14 Байер Фарма Акциенгезельшафт Новые хелатные соединения гадолиния с высокой релаксивностью для применения в магнитно-резонансной визуализации
MX2021006024A (es) 2018-11-23 2021-07-06 Bayer Ag Formulacion de medios de contraste y proceso para prepararlos.
CN109867635A (zh) * 2019-02-14 2019-06-11 华东师范大学 一种t1型胶束磁共振成像造影剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
JPH10112939A (ja) * 1996-10-07 1998-04-28 Nec Corp 電源切替回路
DE19729013A1 (de) * 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis

Also Published As

Publication number Publication date
HUP0300736A3 (en) 2010-01-28
CZ2003392A3 (cs) 2003-09-17
WO2002013874A2 (de) 2002-02-21
CA2419223A1 (en) 2003-02-11
YU10603A (sh) 2006-05-25
AU2001277549B2 (en) 2007-02-08
TWI296931B (en) 2008-05-21
CN1469757A (zh) 2004-01-21
HRP20030173A2 (en) 2005-04-30
BG107542A (bg) 2003-09-30
IL154385A0 (en) 2003-09-17
RU2290206C2 (ru) 2006-12-27
DE10066210B4 (de) 2008-02-28
NZ523932A (en) 2007-07-27
EE200300061A (et) 2004-12-15
AU7754901A (en) 2002-02-25
BR0113188A (pt) 2003-06-24
WO2002013874A8 (de) 2002-06-13
MXPA03001287A (es) 2003-10-06
EP1307236A2 (de) 2003-05-07
ZA200301949B (en) 2004-12-14
SK1572003A3 (en) 2003-10-07
PL365596A1 (en) 2005-01-10
NO20030604L (no) 2003-04-11
KR20030022387A (ko) 2003-03-15
HUP0300736A2 (hu) 2003-09-29
UA82642C2 (uk) 2008-05-12
NO20030604D0 (no) 2003-02-07
JP2004506025A (ja) 2004-02-26

Similar Documents

Publication Publication Date Title
AR034139A1 (es) Uso de complejos metalicos que contienen perfluoralquilo como medios de contraste para representar placas, tumores y necrosis en imagenes por resonancia magnetica
DE60131257D1 (de) Diffusionsbildgebung von gewebe
Min et al. A graphdiyne oxide‐based iron sponge with photothermally enhanced tumor‐specific Fenton chemistry
Li et al. Pulsed ultrasound-modulated optical tomography using spectral-hole burning as a narrowband spectral filter
DE69002767T2 (de) Fluor- und phosphorhaltige amphiphilische moleküle mit oberflächenaktiven eigenschaften.
CY1110851T1 (el) 36p6d5: εκκρινομενο αντιγονο ογκων
DE69939107D1 (de) Bildgebung mittels festkörper-kernmagnetresonanz
DE602005017880D1 (de) Kern-magnetresonanzvorrichtung
Lim et al. Multiplexed imaging of therapeutic cells with multispectrally encoded magnetofluorescent nanocomposite emulsions
Fiel et al. A comparative study of manganese meso-sulfonatophenyl porphyrins: contrast-enhancing agents for tumors
AU3757601A (en) Magnetic resonance apparatus including an rf magnetic flux guiding structure forimproving the signal-to-noise ratio
NO933421D0 (no) Kontrastmiddel
WO2006026770A3 (en) Integrated ewp-stm spin resonance microscope
Yang et al. Multifunctional upconversion nanoparticles for targeted dual-modal imaging in rat glioma xenograft
Zhang et al. Free‐base porphyrins as CEST MRI contrast agents with highly upfield shifted labile protons
Han et al. Development of fluorescence/MR dual-modal manganese-nitrogen-doped carbon nanosheets as an efficient contrast agent for targeted ovarian carcinoma imaging
Francolon et al. Preparation of core/shell NaYF4: Yb, Tm@ dendrons nanoparticles with enhanced upconversion luminescence for in vivo imaging
Paz-Fumagalli et al. Dural" tail" associated with an acoustic schwannoma in MR imaging with gadopentetate dimeglumine.
AU2001277549A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
BR0312552A (pt) Aplicação de complexos de metais contendo perfluoralquila como agente de contraste na imagem de ressonância magnética para a representação de trombos intravasculares
Kobayashi et al. Spectroscopic analysis of the autofluorescence from human bronchus using an ultraviolet laser diode
Kiss et al. Optical and cross-sectional imaging technologies for bladder cancer
Deng et al. Imaging gliomas with nanoparticle-labeled stem cells
Koenig et al. Investigation of the biochemical state of paramagnetic ions in vivo using the magnetic field dependence of 1/T1 of tissue protons (NMRD profile): applications to contrast agents for magnetic resonance imaging
WO2002047537A3 (en) Compositions and methods for in situ and in vivo imaging of cells and tissues

Legal Events

Date Code Title Description
FB Suspension of granting procedure